Vor Biopharma Inc. Research and Development Expense
Vor Biopharma Inc. (VOR) reported Research and Development Expense of $25.92 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-11
- Vor Biopharma Inc. research and development expense for the quarter ending 2026-06-30 was $25.92M, a 90.09% decline year-over-year.
- Vor Biopharma Inc. research and development expense for the quarter ending 2026-03-31 was $17.59M, a 34.10% decline year-over-year.
- Vor Biopharma Inc. research and development expense for the quarter ending 2025-12-31 was $19.19M, a 24.29% decline year-over-year.
- Vor Biopharma Inc. research and development expense for the quarter ending 2025-09-30 was $14.14M, a 35.18% decline year-over-year.
- Vor Biopharma Inc. research and development expense for fiscal 2025 was $321.53M, a 244.58% increase from fiscal 2024.
- Vor Biopharma Inc. research and development expense for fiscal 2024 was $93.31M, a 1.07% decline from fiscal 2023.
- Vor Biopharma Inc. research and development expense for fiscal 2023 was $94.31M, a 46.11% increase from fiscal 2022.
- Vor Biopharma Inc. research and development expense for fiscal 2022 was $64.55M, a 35.81% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $25.92M 10-Q · filed 2026-08-11 | $43.52M 10-Q · filed 2026-08-11 | $62.70M derived: sum of 3 quarters · filed 2026-08-11 | $76.85M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $17.59M 10-Q · filed 2026-05-13 | $36.78M derived: sum of 2 quarters · filed 2026-05-13 | $50.93M derived: sum of 3 quarters · filed 2026-05-13 | $312.43M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $19.19M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $33.33M derived: sum of 2 quarters · filed 2026-03-30 | $294.83M derived: sum of 3 quarters · filed 2026-08-11 | $321.53M 10-K · filed 2026-03-30 |
| 2025-09-30 | $14.14M 10-Q · filed 2025-11-13 | $275.64M derived: sum of 2 quarters · filed 2026-08-11 | $302.34M 10-Q · filed 2025-11-13 | $327.69M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $261.50M 10-Q · filed 2026-08-11 | $288.20M 10-Q · filed 2026-08-11 | $313.55M derived: sum of 3 quarters · filed 2026-08-11 | $335.37M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $26.70M 10-Q · filed 2026-05-13 | $52.05M derived: sum of 2 quarters · filed 2026-05-13 | $73.87M derived: sum of 3 quarters · filed 2026-05-13 | $95.69M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $25.35M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $47.16M derived: sum of 2 quarters · filed 2026-03-30 | $68.99M derived: sum of 3 quarters · filed 2026-03-30 | $93.31M 10-K · filed 2026-03-30 |
| 2024-09-30 | $21.82M 10-Q · filed 2025-11-13 | $43.64M derived: sum of 2 quarters · filed 2025-11-13 | $67.96M 10-Q · filed 2025-11-13 | $88.86M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $21.82M 10-Q · filed 2025-08-12 | $46.15M 10-Q · filed 2025-08-12 | $67.04M derived: sum of 3 quarters · filed 2025-08-12 | $94.65M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $24.32M 10-Q · filed 2025-05-14 | $45.22M derived: sum of 2 quarters · filed 2025-05-14 | $72.83M derived: sum of 3 quarters · filed 2025-05-14 | $96.72M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $20.90M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $48.50M derived: sum of 2 quarters · filed 2025-03-20 | $72.40M derived: sum of 3 quarters · filed 2025-03-20 | $94.31M 10-K · filed 2025-03-20 |
| 2023-09-30 | $27.61M 10-Q · filed 2024-11-07 | $51.50M derived: sum of 2 quarters · filed 2024-11-07 | $73.42M 10-Q · filed 2024-11-07 | $90.48M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $23.90M 10-Q · filed 2024-08-08 | $45.81M 10-Q · filed 2024-08-08 | $62.87M derived: sum of 3 quarters · filed 2024-08-08 | $79.75M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $21.91M 10-Q · filed 2024-05-09 | $38.98M derived: sum of 2 quarters · filed 2024-05-09 | $55.85M derived: sum of 3 quarters · filed 2024-05-09 | $71.19M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $17.06M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-20 | $33.94M derived: sum of 2 quarters · filed 2024-03-20 | $49.27M derived: sum of 3 quarters · filed 2024-03-20 | $64.55M 10-K · filed 2024-03-20 |
| 2022-09-30 | $16.88M 10-Q · filed 2023-11-07 | $32.21M derived: sum of 2 quarters · filed 2023-11-07 | $47.49M 10-Q · filed 2023-11-07 | $60.18M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $15.33M 10-Q · filed 2023-08-10 | $30.61M 10-Q · filed 2023-08-10 | $43.31M derived: sum of 3 quarters · filed 2023-08-10 | $56.23M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $15.28M 10-Q · filed 2023-05-11 | $27.97M derived: sum of 2 quarters · filed 2023-05-11 | $40.90M derived: sum of 3 quarters · filed 2023-05-11 | $53.87M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $12.69M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $25.62M derived: sum of 2 quarters · filed 2023-03-23 | $38.59M derived: sum of 3 quarters · filed 2023-03-23 | $47.53M 10-K · filed 2023-03-23 |
| 2021-09-30 | $12.93M 10-Q · filed 2022-11-10 | $25.89M derived: sum of 2 quarters · filed 2022-11-10 | $34.84M 10-Q · filed 2022-11-10 | $46.17M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $12.97M 10-Q · filed 2022-08-11 | $21.91M 10-Q · filed 2022-08-11 | $33.24M derived: sum of 3 quarters · filed 2022-08-11 | $41.38M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $8.94M 10-Q · filed 2022-05-12 | $20.27M derived: sum of 2 quarters · filed 2022-05-12 | $28.41M derived: sum of 3 quarters · filed 2022-05-12 | $34.39M derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $11.33M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-14 | $19.47M derived: sum of 2 quarters · filed 2022-03-14 | $25.45M derived: sum of 3 quarters · filed 2022-03-14 | $31.62M 10-K · filed 2022-03-14 |
| 2020-09-30 | $8.14M 10-Q · filed 2021-11-10 | $14.12M derived: sum of 2 quarters · filed 2021-11-10 | $20.29M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $5.97M 10-Q · filed 2021-08-09 | $12.15M 10-Q · filed 2021-08-09 | ||
| 2020-03-31 | $6.17M 10-Q · filed 2021-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |